Nanjing Sanhome Pharmaceutical Co., Ltd.

Chunhuan Jiang

Yong Wang

Liwen Zhao

Hai Feng Wang

Yan Mei Zhang

Hai Jun Wang

Yazhou Wang

Chao Li

Qi Liu

Xiaorong Liu

Chen Wang

Hongyan Chen

Xu Quan

Guochuang Zheng

Dandan Huang

Silin Pang

Bingyang Ge

Wei Hai

Hongfeng Gu

Xinsheng Shi

Shengwei Yang

Yexin Liao

Menghua Chen

Yan Zhang

Hai Wang

Disclosed are a class of compounds which are inhibitors of acetyl-CoA carboxylase (ACC) and the use thereof. In particular, provided are compounds as shown in formula I or isomers, pharmaceutically acceptable salts, solvates, crystals or prodrugs thereof, and methods for preparing the same, and pharmaceutical compositions comprising the compounds and the use of the compounds or compositions for treating and/or preventing diseases associated with ACC expression, such as fibrotic diseases, metabolic diseases, cancers or tissue hyperplasia diseases. The compound has a good inhibitory activity against ACC and shows good promise to be a therapeutic drug for fibrotic diseases, metabolic diseases, cancers or tissue hyperplasia diseases. 

Compound as ACC inhibitor and use thereof

Provided are a chemical compound of an isocitrate dehydrogenase inhibitor, and an application thereof, belonging to the field of medicinal chemistry; specifically provided is the chemical compound represented by formula I, or its isomer, pharmaceutically acceptable salt, crystal, solvate, or prodrug, as well as their preparation methods and pharmaceutical compositions containing said chemical compound, and an application of said chemical compound or composition. The chemical compound has very good ability to inhibit mutant IDH2 enzyme activity and to inhibit mutant IDH2 neoplastic cells, and may be used for preventing and/or treating a tumor characterized by the presence of mutant IDH2.

Chemical compound of isocitrate dehydrogenase inhibitor, and application thereof

Growing community of inventors

Jiangsu, China

Chunhuan Jiang